Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma

Trevor McKibbin¹, John C. Panetta²,³, Maryam Fouladi⁴, Amar Gajjar⁴, Feng Bai³, M. Fatih Okcu⁵, and Clinton F. Stewart¹,³

Abstract

Purpose: We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters.

Experimental Design: We assessed the pharmacokinetics of amifostine and WR1065 in 33 children who received amifostine (1-minute infusion, 600 mg/m²) just before the start of and 3 hours into a 6-hour cisplatin infusion. Serial blood samples were collected after doses 1 (0 hour) and 2 (3 hours) of course 1. Amifostine and WR1065 were quantitated by high performance liquid chromatography with electrochemical detection. A pharmacokinetic model was simultaneously fit to amifostine and WR1065 plasma or whole blood concentration-versus-time data. The influence of demographic, biochemical, and pharmacogenetic covariates on amifostine and WR1065 disposition was evaluated.

Results: Body surface area was the primary size-based covariate for amifostine pharmacokinetics explaining 53% and 56% of interindividual variability in plasma and whole-blood amifostine clearance, respectively. The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from the plasma data were 107 L/h/m², 5.53 L/m², and 30.6 L/h/m². The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from whole blood data were 136 L/h/m², 7.23 L/m², and 12.5 L/h/m².

Conclusions: These results support using body surface area for calculating doses of amifostine in children. Similar to data in adults, amifostine and WR1065 are rapidly cleared from plasma and whole blood in children. Clin Cancer Res; 16(3); 1049–57. ©2010 AACR.

Medulloblastoma is the most common childhood central nervous system malignancy (1). The use of cisplatin for the treatment of medulloblastoma has improved overall survival and enabled use of lower doses of cranial spinal irradiation (2, 3). However, cisplatin carries with it a host of both short- and long-term toxicities including significant ototoxicity. Approximately 35% of children treated with cisplatin for medulloblastoma have significant ototoxicity (2, 4). Amifostine significantly reduces the risk of severe ototoxicity in patients with average-risk medulloblastoma receiving dose-intensive chemotherapy when administered before and during the cisplatin infusion (5).

Amifostine is a prodrug converted to the active thiol metabolite WR1065, which acts as a nonspecific cytoprotectant, reducing the toxicity associated with alkylating agents and radiation therapy by scavenging free radicals (6). The conversion of amifostine to WR1065 is catalyzed by alkaline phosphatase and is pH dependent, occurring more rapidly in alkaline pH. The lower concentration of membrane-bound alkaline phosphatase and lower pH in tumor environments contribute to a relatively low concentration of active chemoprotectant in malignant tissues, providing a relatively selective cytoprotection of normal tissues (7–9). The half-life of amifostine is ~9 minutes, whereas that of the active metabolite, WR1065, is ~15 minutes. Thus, the schedule of amifostine administration is potentially an important factor for optimum efficacy (7, 10, 11).

Despite a promising mechanism of action for the selective protection of normal tissues, investigations of the cytoprotective effects of amifostine have yielded mixed results (5, 12, 13). These conflicting findings may be related to differences in the schedule and dosage of amifostine, inadequate statistical power, and differences in the underlying chemotherapy and patient populations studied. Fouladi and colleagues (14) conducted a phase 1 evaluation of amifostine in combination with

Authors’ Affiliations: Departments of ¹Clinical Pharmacy and ²Pharmaceutical Sciences, University of Tennessee; Departments of ³Pharmaceutical Sciences and ⁴Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee; and ⁵Texas Children’s Cancer Center; Department of Pediatrics, Hematology-Oncology, Baylor College of Medicine, Houston, Texas

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Corresponding Author: Clinton F. Stewart, Pharmaceutical Sciences Department, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-2794. Phone: 901-595-3665; Fax: 901-525-6869; E-mail: clinton.stewart@stjude.org.

doi: 10.1158/1078-0432.CCR-09-1997
©2010 American Association for Cancer Research.
a 6-hour cisplatin infusion and concluded that the optimum schedule was 600 mg/m² just before and 3 hours into a 6-hour cisplatin infusion. This schedule of administration significantly reduced the ototoxicity associated with the treatment of medulloblastoma (5). To date, investigations of the pharmacokinetic parameters of amifostine and WR1065 in pediatric patients remain limited.

Amifostine and WR1065 are involved in a complex interaction with the glutathione pathway. In vitro exposure of cells to WR1065 results in increased precursor uptake and biosynthesis of glutathione (13). Additionally, the elimination of WR1065 may be partially mediated as a glutathione conjugate (16). Significant functional polymorphisms in the glutathione S-transferase (GST) pathway have been discovered, with implications for the clearance of multiple drugs including chemotherapeutics (17–20). These polymorphisms include GSTM1*0, in which the gene is deleted. Homozygous patients express no M1 protein. GSTT1 is also polymorphic with homozygotes lacking the GST T1 function. The GSTP1 polymorphism involves a single nucleotide polymorphism resulting in an amino acid substitution. A resulting steric effect on substrate binding causes substrate-specific functional effects (17, 21). Evaluating functional polymorphisms as covariates for pharmacokinetic parameters may help explain variability in amifostine and WR1065 clearance.

Analytic procedures for measuring amifostine and WR1065 have been developed for both plasma and whole blood. To date, it is not known which sampling matrix provides a better model for relating pharmacokinetics to pharmacodynamics (10, 11, 16). WR1065 is rapidly autoxidized, creating a scenario in which sample preparation and procedures for arresting oxidation may have significant implications for the concentrations measured (10, 16, 22). The analytic procedure used in this investigation permitted simultaneous bioanalytic measurements in both blood and plasma (23).

The objectives of this investigation were to: (a) simultaneously assess the pharmacokinetics of amifostine and WR1065 in pediatric patients treated with cisplatin for medulloblastoma; (b) estimate the magnitude of interpatient pharmacokinetic variability along with individual estimates of patient pharmacokinetic parameters; (c) investigate the effects of baseline clinical variables and functional polymorphisms of GST M1, T1, and P1 on the variability of the pharmacokinetic parameter; (d) evaluate parameter estimates derived from whole blood and plasma sampling in relation to pharmacodynamic effects of amifostine; and (d) use the current data set to develop a limited sampling model (LSM) for future investigations of amifostine pharmacokinetics.

Materials and Methods

Patients and treatment. The population pharmacokinetic analysis included amifostine and WR1065 plasma and whole-blood concentration-time data from children that participated in the protocol St. Jude Medulloblastoma-96 (5, 24). Eligibility criteria included patients ages ≥3 and ≤21 y at the time of diagnosis who had not previously received chemotherapy or irradiation. Prior corticosteroid therapy was allowed. Patients were required to begin treatment within 28 d of definitive surgery. Medulloblastoma risk category was classified according to a modified Chang staging system, as previously described (24). Additional eligibility criteria included normal renal function, normal liver function, normal bone marrow function (hemoglobin of ≥10 g/dL, WBC count of ≥3,000/mL, absolute neutrophil count of ≥1,500/mL, and platelets of ≥100,000/mm³), and an the Eastern Cooperative Oncology Group performance score of 0 to 3, except in cases of posterior fossa syndrome. Informed consent was obtained from the parent/guardian or patient per the St. Jude Children’s Research Hospital Institutional Review Board.

All patients underwent an attempt at maximal surgical resection of the tumor and received treatment with radiation and chemotherapy as previously described (24). After a 6-wk rest period, patients began four cycles of high-dose chemotherapy, each followed by stem cell or bone marrow rescue. The high-dose chemotherapy included 75 mg/m² cisplatin and 1.5 mg/m² vincristine (2 mg max) on day −4, followed by a continuous infusion of 2 g/m² cyclophosphamide with 2-mercaptoethane sulfonic acid on days −3 and −2, hydration on day −1, and infusion of peripheral blood stem cells or bone marrow on day 0, with supportive care and filgrastim in the following days and a 6-wk rest period, patients began four cycles of high-dose chemotherapy, each followed by stem cell or bone marrow rescue. The high-dose chemotherapy included 75 mg/m² cisplatin and 1.5 mg/m² vincristine (2 mg max) on day −4, followed by a continuous infusion of 2 g/m² cyclophosphamide with 2-mercaptoethane sulfonic acid on days −3 and −2, hydration on day −1, and infusion of peripheral blood stem cells or bone marrow on day 0, with supportive care and filgrastim in the following days and a subsequent dose of 1.5 mg/m² vincristine (2 mg max) on day +6. Amifostine (600 mg/m²) was administered with each cycle of cisplatin containing chemotherapy as a 1-min i.v. infusion just before the start and 3 h into the 6-h cisplatin infusion.

Blood and plasma sampling and bioanalysis. Samples were obtained preinfusion, 2, 5, 10, 30, 60, 120, and 180 min after both the first and second amifostine dose during course one of cisplatin. Plasma and whole blood concentrations of amifostine and WR1065 were assayed.
as previously described (23). In short, for each sample, the concentration of native WR1065 was determined. To measure the concentration of amifostine, a sample was incubated for 4 h at 37°C to convert amifostine to WR1065. After incubation, the sample was assayed to determine the concentration of WR1065. This concentration of WR1065 represented the concentration of amifostine (converted) plus the native WR1065 previously assayed. Subtraction of the native WR1065 concentration from the converted WR1065 determined the concentration of amifostine. The lower limit of quantitation (LLQ) of amifostine and WR1065 was 0.25 μmol/L. The bioanalytic procedure was done for both whole blood and plasma for each sampling time.

Pharmacogenetic analysis. We hypothesized the no or low-activity GST genotypes (GSTP1*1A, GSTM1 null, and GSTT1 null) would result in altered systemic clearance of amifostine and WR1065. We used a multiplex PCR technique to amplify both GSTM1 and GSTT1 simultaneously in a single PCR as described in detail before (25). In analyses, patients with null genotypes were compared with patients with nonnull genotypes. We determined GSTM1 rs1695 and rs1138272 polymorphisms by PCR and RFLP methods as described before (25). We analyzed the results by comparing patients with the *A/*A genotype with *A/*G and *G/*G genotypes (A, GSTM1 null, and *G, GSTM1 nonnull). A patient with at least one variant allele. For quality control, 10% of all of the samples were repeated.

Pharmacokinetic analysis. The pharmacokinetics of amifostine and WR1065 were determined by nonlinear mixed effects modeling through NONMEM (version VI, Globomax LLC), using the first-order conditional estimation method with INTERACTION through the ADVAN7 subroutine (26). Plasma and whole blood concentration-time data were modeled separately. Xpose (27), Census (28), and the R-project (version 2.8.1) were used for data management and visualization. Posterior Bayesian individual estimates of amifostine and WR1065 pharmacokinetic parameters were obtained within NONMEM. The pharmacokinetic parameters estimated included amifostine systemic clearance (CLam), volume of distribution (VD), amifostine intercompartmental rate constants k12 and k21, apparent clearance of WR1065 (CLwr), and WR1065 intercompartmental rate constants k34 and k43 (Fig. 1). The pharmacokinetic model assumed that the VD of amifostine was equal to the VD of WR1065.

The distribution of parameters was assumed to be log normal. Both interindividual (IIV) and interoccasion (IOV) variability in parameters were modeled as exponential terms. An occasion was defined as one dosing occasion of amifostine. The residual errors for amifostine and WR1065 were each modeled independently using a mixed proportional and additive error model:

\[ C_{\text{pi}} = \hat{C}_{\text{pa}}(1 + \varepsilon_{\text{pi}}^{\text{rel}}) + \varepsilon_{\text{pi}}^{\text{abs}} \]

where \( \hat{C}_{\text{pa}} \) and \( \hat{C}_{\text{p}} \) represent the \( k_{\text{ab}} \) actual and predicted concentrations in individual \( i \), respectively. The error terms \( \varepsilon_{\text{pi}}^{\text{rel}} \) and \( \varepsilon_{\text{pi}}^{\text{abs}} \) are the components of the proportional and additive error, respectively. The proportional error was assumed to have a mean of zero and variance of \( \sigma \). The components of additive error for amifostine and WR1065 were both fixed to 0.25 in consideration of the LLQ of the assay (0.25 μmol/L). Observed amifostine and WR1065 concentrations below the LLQ were substituted with 0.125 (1/2*LLQ).

Covariates considered in the analysis included body surface area (BSA), age, gender, race, albumin, total bilirubin, GST polymorphisms (M1, T1, and P1), serum creatinine, and calculated glomerular filtration rate (29). A covariate was considered significant in this analysis if the addition of the covariate to the model reduced the objective function value (OFV) at least 3.84 units (\( P < 0.05 \), based on the \( \chi^2 \) test for the difference in the −2 log-likelihood between two hierarchical models that differ by 1 degree of freedom).

The relationships between the pharmacokinetic parameters (CLam, VD, and CLwr) and categorical or continuous covariates were described using the following model:

\[ \theta = \hat{\theta} + \sum_{\rho = 1}^{m} \text{covariate}_{\rho} \times \theta_{\rho} \]

where \( \theta \) was the population estimate, \( \hat{\theta} \) was the population estimate with none of the covariates included, and \( \theta_{\rho} \) was the effect of covariate \( \rho \) on the model. When a categorical variable was considered, the presence of a covariate was coded as covariate \( \rho = 1 \) and its absence as covariate \( \rho = 0 \). When sex was evaluated as a covariate, male patients were coded as \( \rho = 0 \) and females as \( \rho = 1 \). Patients with incomplete data were censored when covariate analysis included variables for which data were missing.

Bootstrap analysis was used to evaluate robustness of models and calculate SEM estimates and 95% confidence intervals for parameters (30). The nonparametric bootstrap procedure used random sampling from the data used
for building the base population pharmacokinetic model
with replacement to create bootstrap data sets \( n = 500 \)
with the same sample size as the original. Each new data
set was fit to the final model, and population variables
were estimated. This procedure was done separately for
the plasma and whole blood data sets.

**Pharmacodynamic assessment.** The primary adverse
events of amifostine are hypotension, nausea, and hypo-
calcemia related to transient hypoparathyroidism (5). We
sought to determine whether parameter estimates de-

erived from whole blood or plasma sampling would pro-

provide a more robust model in relating pharmacokinetic
assessments to the pharmacodynamic effects of amifostine
(hypocalcemia and hypoparathyroidism). The decrease
from baseline and the duration of decrease in ionized cal-
cium values and parathyroid hormone (PTH) values were
used to assess relationships between pharmacokinetic
parameters and toxicity with both plasma and whole
blood-derived data. Sampling of ionized calcium and
PTH was done before and during the 24 h after the
amifostine infusion.

**Selection of pharmacokinetic LSM.** We used the plasma
amifostine and WR1065 data to create a LSM for use in
future clinical trials of amifostine. The LSM was deter-

mined using the estimated population pharmacokinetic
parameters in the plasma data. A stepwise process was
used to determine an adequate LSM that would estimate
individual post hoc CLam, VD, and CLWR. The following
sampling strategies were evaluated: two samples from
one amifostine dose or occasion (5 and 30 min), two sam-
ple from each of two occasions (5 and 30 min), three
samples from one occasion (5, 30, and 60 min), and three
samples from each of two occasions (5, 30, and 60 min).

The following process was used to evaluate limited sam-
pling strategies. First, the concentration-time data were
limited to the sampling times of interest. The individual
post hoc estimates were obtained in NONMEM with each
of the limited sampling data sets using the population es-

timates from the final BSA-normalized plasma model as
population priors. This process was repeated for each sam-
pling strategy evaluated. The individual post hoc estimates
from each limited sampling strategy were then compared
with the post hoc estimates from the full base model, and
the relative bias and accuracy were calculated.

The Wilcoxon signed-rank test was used to compare in-
dividual post hoc estimates from each of the limited sam-
pling strategies to the post hoc estimates from the full base
model. All statistical tests used a two-tailed significance
threshold of \( P < 0.05 \) without correction for multiple test-
ing. Statistical analyses were carried out using the JMP
software v7.0.1 (SAS Corp.).

**Results**

**Patient population.** Of the 134 patients that underwent
treatment on the protocol St. Jude Medulloblastoma-96
and received amifostine, 49 consented to participate in
the pharmacokinetic studies. One patient enrolled in phar-
macokinetic studies was unable to contribute samples due
to hypotension-related to amifostine administration. Dur-
ing the WR1065 assay development, it was determined
that because of WR1065 instability, samples assayed
\( >48 \) hours after collection were not evaluable (23). This
restriction created a data set of 33 patients with 649 eval-
uable whole blood samples and 33 patients with 711 eval-
uable samples in plasma. Baseline patient characteristics
of the patients with pharmacokinetic sampling were com-
parable with those of the full clinical trial population (24)
and are provided in Table 1.

**Amifostine and WR1065 disposition.** Results from phar-
macokinetic studies of amifostine and WR1065 in adult
patients showed that a four-compartment model ade-
quately described their disposition (10). We also used a
model with a total of four compartments to simultane-
ously model amifostine (two compartments) and WR1065
(two compartments) with a rate constant describing the
conversion of amifostine to WR1065 (Fig. 1). Using the
plasma amifostine and WR1065 concentration-
time data, the amifostine population pharmacokinetic

<table>
<thead>
<tr>
<th>Table 1. Baseline patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient characteristic</strong></td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Medulloblastoma risk category</strong></td>
</tr>
<tr>
<td>High</td>
</tr>
<tr>
<td>Average</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Race</td>
</tr>
<tr>
<td>Caucasian</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>GST genotype (n = 25)</strong></td>
</tr>
<tr>
<td>M1</td>
</tr>
<tr>
<td>Present</td>
</tr>
<tr>
<td>Null</td>
</tr>
<tr>
<td>T1</td>
</tr>
<tr>
<td>Present</td>
</tr>
<tr>
<td>Null</td>
</tr>
<tr>
<td>P1</td>
</tr>
<tr>
<td>wt</td>
</tr>
<tr>
<td>Variant</td>
</tr>
</tbody>
</table>

**Abbreviation:** wt, wild-type.
parameter estimates included $\text{CL}_{\text{am}}$, $\text{VD}$, $k_{12}$, and $k_{21}$, and were 107 L/h, 5.62 L, 3.02 h$^{-1}$, and 4.99 h$^{-1}$, respectively (Table 2). Population pharmacokinetic parameters of plasma WR1065 included $\text{CL}_{\text{WR}}$, $k_{34}$, and $k_{43}$, and were 30.1 L/h, 55.3 h$^{-1}$, and 14.3 h$^{-1}$, respectively.

The same structural model was used for the whole blood amifostine and WR1065 concentration-time data. The whole blood amifostine pharmacokinetic parameter estimates included $\text{CL}_{\text{am}}$, $\text{VD}$, $k_{12}$, and $k_{21}$ and were 135 L/h, 25.1 h$^{-1}$, and 12.9 h$^{-1}$ for $\text{CL}_{\text{am}}$, $k_{34}$, and $k_{43}$, respectively.

The plasma and whole blood estimates of IIV for amifostine clearance were 56% and 55%, respectively. The respective plasma and whole blood estimates of IIV for $\text{CL}_{\text{WR}}$ in plasma and whole blood were 58% and 39%, respectively.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NONMEM estimate</th>
<th>Mean Bootstrap estimate</th>
<th>Bootstrap SEE</th>
<th>Bootstrap 95% CI</th>
<th>NONMEM IIV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\text{CL}_{\text{am}}$ (L/h/m$^2$)*</td>
<td>107</td>
<td>106</td>
<td>8.41</td>
<td>90.3–123</td>
<td>0.15 (38)</td>
</tr>
<tr>
<td>$\text{CL}_{\text{am}}$ (L/h)</td>
<td>107</td>
<td>106</td>
<td>11.5</td>
<td>86.3–130</td>
<td>0.31 (56)</td>
</tr>
<tr>
<td>$\text{CL}_{\text{am}}$ (L/h/m$^2$)*</td>
<td>136</td>
<td>133</td>
<td>10.7</td>
<td>113–155</td>
<td>0.13 (36)</td>
</tr>
<tr>
<td>$\text{CL}_{\text{am}}$ (L/h)</td>
<td>135</td>
<td>132</td>
<td>14.2</td>
<td>105–160</td>
<td>0.3 (55)</td>
</tr>
<tr>
<td>$\text{VD}$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma (L/m$^2$)*</td>
<td>5.53</td>
<td>5.51</td>
<td>0.55</td>
<td>4.53–6.60</td>
<td>0.12 (34)</td>
</tr>
<tr>
<td>Plasma (L)</td>
<td>5.62</td>
<td>5.51</td>
<td>0.72</td>
<td>4.36–7.03</td>
<td>0.32 (56)</td>
</tr>
<tr>
<td>Blood (L/m$^2$)*</td>
<td>7.23</td>
<td>6.97</td>
<td>1.04</td>
<td>4.73–8.71</td>
<td>0.08 (28)</td>
</tr>
<tr>
<td>Blood (L)</td>
<td>7.14</td>
<td>6.84</td>
<td>1.2</td>
<td>4.27–8.92</td>
<td>0.23 (48)</td>
</tr>
<tr>
<td>$\text{CL}_{\text{WR}}$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma (L/h/m$^2$)*</td>
<td>30.6</td>
<td>31.3</td>
<td>4.46</td>
<td>22.4–40.4</td>
<td>0.34 (58)</td>
</tr>
<tr>
<td>Plasma (L/h)</td>
<td>30.1</td>
<td>30.9</td>
<td>4.26</td>
<td>22.4–39.4</td>
<td>0.34 (58)</td>
</tr>
<tr>
<td>Blood (L/h/m$^2$)*</td>
<td>12.5</td>
<td>13.4</td>
<td>2.87</td>
<td>9.6–20.5</td>
<td>0.17 (42)</td>
</tr>
<tr>
<td>Blood (L/h)</td>
<td>12.7</td>
<td>13.7</td>
<td>3.1</td>
<td>9.64–21</td>
<td>0.15 (39)</td>
</tr>
</tbody>
</table>

Population parameters with sex as a covariate

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NONMEM estimate</th>
<th>Mean Bootstrap estimate</th>
<th>Bootstrap SEE</th>
<th>Bootstrap 95% CI</th>
<th>NONMEM IIV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\text{CL}_{\text{am}}$ (L/h/m$^2$)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>99</td>
<td>99</td>
<td>8.7</td>
<td>82.6–117</td>
<td>0.15 (39)</td>
</tr>
<tr>
<td>Female</td>
<td>24.2</td>
<td>2.7</td>
<td>9.2</td>
<td>3.7–39.4</td>
<td>—</td>
</tr>
<tr>
<td>Blood (L/h/m$^2$)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>136</td>
<td>133</td>
<td>11.2</td>
<td>112–158</td>
<td>0.13 (36)</td>
</tr>
<tr>
<td>Female</td>
<td>−0.67</td>
<td>−0.08</td>
<td>12.5</td>
<td>−24.7 to 26.5</td>
<td>—</td>
</tr>
<tr>
<td>$\text{VD}$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma (L/m$^2$)*</td>
<td>5.41</td>
<td>5.39</td>
<td>0.56</td>
<td>4.4–6.52</td>
<td>0.13 (36)</td>
</tr>
<tr>
<td>Blood (L/m$^2$)*</td>
<td>7.23</td>
<td>6.95</td>
<td>1.1</td>
<td>4.7–8.7</td>
<td>0.08 (28)</td>
</tr>
<tr>
<td>$\text{CL}_{\text{WR}}$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma (L/m$^2$)*</td>
<td>31.2</td>
<td>31.9</td>
<td>4.5</td>
<td>23–40.8</td>
<td>0.33 (57)</td>
</tr>
<tr>
<td>Blood (L/m$^2$)*</td>
<td>12.5</td>
<td>13.4</td>
<td>2.9</td>
<td>9.7–20.9</td>
<td>0.17 (41)</td>
</tr>
</tbody>
</table>

Abbreviations: SEE, SEM of the estimate; 95% CI, percentile bootstrap 95% confidence interval; Δ female, population estimated difference in clearance in female patients.

*Indicates estimate from BSA-normalized model.
weight as a covariate explained 46% and 62% of the respective IIV in systemic clearance and volume of amifostine in plasma, which although significant was not as much of an effect as BSA. Thus, BSA normalization was incorporated in the base model and remained in all subsequent analyses of the population model.

The estimates of IOV for Clam were 19% and 27% in the respective plasma and whole blood BSA-normalized models. Inclusion of IOV decreased the OFV by 32 and 71 in the respective plasma and whole blood models. The addition of IOV to the plasma model decreased the estimate of proportional residual error for amifostine from 0.19 (44%) to 0.13 (36%; Table 3). In the BSA-adjusted whole blood model, the addition of IOV decreased the estimate of proportional residual error for amifostine from 0.33 (57%) to 0.19 (44%). The BSA-normalized model with IOV was used to screen each additional covariate in both plasma and whole blood data.

Of the three GST polymorphisms evaluated, the GST P1 polymorphism provided the most promising results. Addition of the GST P1 polymorphism to the plasma model (homozygous versus variant) decreased IIV by 2.5%, but the change in objective function did not reach statistical significance (DOFV = 2.5%; P = 0.08). None of the other GST polymorphisms resulted in significant decreases in measures of variability or improved diagnostic plots when evaluated in relation to amifostine or WR1065 pharmacokinetics in either the plasma or whole blood models.

In the covariate modeling, sex was found as a significant determinant of Clam but not volume or Clavr in the plasma model (DOFV = −7.4; P = 0.007). The estimated typical Clam in the plasma model was 99 and 123 L/hr/m² in males and females, respectively (Table 2). The addition of sex to the model in whole blood data did not result in a decrease of the OFV or IIV. In addition, including sex as a covariate in the whole blood–based model did not change the estimate of residual proportional error for amifostine or WR1065 (Table 3).

The model-predicted and individual-predicted concentrations versus observed concentrations of amifostine/WR105 in plasma and whole blood using the final model are represented as scatter plots in Supplementary Figs. S1 and S2. Considering that the model predictions were symmetrically distributed around the line of identity, we conclude that the BSA-normalized model with IOV adequately describes amifostine and WR1065 disposition. The population pharmacokinetic concentration-time curves from the final models as well as observed values for amifostine and WR1065 concentrations are displayed in Fig. 3. The intercompartmental rate parameter estimates (k_{12}, k_{21}, k_{34}, and k_{43}) from the initial and final models are available in Supplementary Table S3.

**Pharmacodynamic assessment.** We sought to develop a model to investigate the relationships between plasma- and whole blood–derived amifostine and WR1065 pharmacokinetic parameters, and drug effect, namely hypocalcemia and PTH values. A total of 32 patients had baseline and follow-up ionized calcium measurements. Of these patients, 12 (38%) had a decrease in serum-ionized calcium to below 1 mmol/L (reference range, 1.12–1.31 mmol/L). Of these 32 patients, 31 received calcium chloride infusions either to prevent or as a result of hypocalcemia. Visual inspection of the change and duration of change in ionized calcium values did not reveal any relationships between this marker of drug effect and pharmacokinetics of amifostine and WR1065 in plasma or whole blood.

Baseline PTH values were available in 18 patients. All but one of the patients with measurements dropped below the level of detection for the assay (10 pg/mL), and only 7 patients had adequate sampling to determine a time to recovery; all of these patients recovered to normal values within 18 to 24 hours (Supplementary Fig. S4). An additional five patients had sampling out to 19 hours postamifostine, but had not yet recovered to the reference range. Visual inspection of the PTH measurements did not reveal any relationships between this pharmacodynamic marker and plasma or blood pharmacokinetics.

### Table 3. Proportional residual error in plasma and whole blood pharmacokinetic models

<table>
<thead>
<tr>
<th>BSA-normalized models</th>
<th>Amifostine Residual error (%)</th>
<th>WR1065 Residual error (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without IOV</td>
<td>0.19 (44)</td>
<td>0.20 (45)</td>
</tr>
<tr>
<td>With IOV</td>
<td>0.13 (36)</td>
<td>0.19 (44)</td>
</tr>
<tr>
<td>With sex and IOV</td>
<td>0.19 (44)</td>
<td>0.13 (36)</td>
</tr>
<tr>
<td>Whole blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without IOV</td>
<td>0.33 (57)</td>
<td>0.12 (35)</td>
</tr>
<tr>
<td>With IOV</td>
<td>0.19 (44)</td>
<td>0.13 (36)</td>
</tr>
<tr>
<td>With sex and IOV</td>
<td>0.19 (44)</td>
<td>0.13 (36)</td>
</tr>
</tbody>
</table>
**Limited sampling model.** Data from 33 patients were used to create a pharmacokinetic LSM to enhance the ability to conduct studies of amifostine disposition in patient populations. The median biases for $\text{CL}_{\text{am}}$ and $\text{CL}_{\text{WR1065}}$ from the LSM with two samples (5 and 30 minutes) from one amifostine dose (occasion) were 3.6% (SD, 46) and 30.7% (SD, 60), respectively. When a third sample was added (1 hour) to the one-occasion sampling strategy, the bias estimates for $\text{CL}_{\text{am}}$ decreased to 3% (SD, 52) but increased to 37% (SD, 52) for apparent WR1065 clearance.

When a second occasion was added to the two-sample strategy (total of four samples) the biases for $\text{CL}_{\text{am}}$ and $\text{CL}_{\text{WR1065}}$ were $-1.24\%$ (SD, 15) and $-9\%$ (SD, 46), respectively. For the strategy that required three samples on each of two occasions, the mean biases for $\text{CL}_{\text{am}}$ and $\text{CL}_{\text{WR1065}}$ were 0.2% (SD, 12.2) and 13% (SD, 24), respectively. Of the models evaluated, the LSM with two samples from two occasions and three samples from two occasions resulted in the lowest calculated biases and were further compared with each other. The estimates of individual pharmacokinetic parameters were not significantly different between these two models for both $\text{CL}_{\text{am}}$ ($P = 0.8$) and $\text{CL}_{\text{WR1065}}$ ($P = 0.9$).

For all of the limited sampling strategies evaluated, the individual parameter estimates for $\text{CL}_{\text{am}}$ were not statistically significantly different from those obtained with the full data set. However, the estimates for $\text{CL}_{\text{WR1065}}$ from the LSM with two and three samples from one occasion were significantly different when compared with those obtained from the full model ($P < 0.0001$ for both). Similarly, the estimates for $\text{CL}_{\text{WR1065}}$ from the LSM with two samples from two occasions and three samples from two occasions were also significantly different from the parameters derived from the full data set with respective $P$ values of 0.005 and 0.001.

**Discussion**

This is the first population analysis of amifostine and WR1065 pharmacokinetics in a pediatric population. This analysis used a validated bioanalysis technique to measure amifostine and WR1065 in both plasma and whole blood and took advantage of the availability of sampling from both plasma and whole blood to model the data from both analytic matrices (23). The analysis identified a large component of variability between subjects and occasions, indicating large differences in exposure among different patients given the same dosage. BSA was identified as the primary size-based covariate, explaining 52% and
57% of the variability in amifostine clearance in the plasma and whole blood models, respectively. Gender was identified as a significant predictor of amifostine clearance in the plasma model. Possible explanations for the more rapid decline in plasma amifostine in female patients compared with male patients include the following: potential differences in metabolism; females may have a faster distribution of drug from serum to tissue; or there might be a slower redistribution back to blood from peripheral tissues. This finding was not confirmed when modeled in the whole blood data. Lacking a specific mechanism that explains these results, the differences in clearance between male and female children observed in the plasma data requires further evaluation in future investigations.

WR1065 has several potential pathways for elimination; it may undergo auto-oxidation and may form bonds with mixed disulfides. Among the potential pathways of elimination is conjugation with glutathione (16). We evaluated three functional polymorphisms in the glutathione pathway, none of which significantly explained variability in the pharmacokinetics of amifostine or WR1065. This may be because other pathways are available for the elimination of WR1065, or because with 25 patients with evaluable genotyping, this analysis was unable to elucidate all significant explanatory variables. Addition of GSTP1 genotype as a covariate for systemic amifostine plasma clearance resulted in a trend, but was not statistically significant. Inclusion of GSTP1 genotype in future investigations of amifostine and WR1065 pharmacokinetics may clarify the role of glutathione pathway polymorphisms in amifostine distribution.

We sought to evaluate the plasma- and whole blood-derived pharmacokinetic estimates with regard to their relationships with measures of the pharmacodynamic effects of amifostine, specifically, hypocalcemia and hyperparathyroidism. As this dosage of amifostine reliably resulted in hypocalcemia, many patients received calcium in a preventative manner, before amifostine. Administration of calcium can also influence PTH levels, potentially masking pharmacokinetic and pharmacodynamic relationships. Nearly all patients with PTH level measurements dropped below the level of quantitation for the clinical assay used. Thus, the measures of ionized calcium and PTH were insufficient to accurately model the pharmacodynamic effects of amifostine. These data highlight the difficulty of pharmacodynamic modeling in the complex milieu of the clinical environment and illustrate the need for early interim analyses to identify potential problems with study measures.

Overall, other than the WR1065 component, the plasma and whole blood models resulted in similar parameter estimates. Expression of alkaline phosphatase, the enzyme that catalyzes the conversion of amifostine to WR1065, on nucleated blood cells may have contributed to the slightly higher typical value of CLam in the whole blood (31). A previous investigation of amifostine concentrations in the whole blood, plasma, and blood elements of five patients reported similar WR1065 concentrations in plasma, whole blood, and blood cells (32, 33), whereas our data suggested higher concentrations of WR1065 in the whole blood compared with plasma. These disparate findings may be related to differences in analytic procedures, such as the methods used to arrest the oxidation of WR1065. Our methods included optimizing perchloric acid concentrations and the immediate immersion of samples into ice to decrease auto-oxidation (23).

The lack of a validation cohort may be considered as a limitation to this investigation. However, the same structural model was used to separately fit data derived from plasma and whole blood sampling. Further investigations would be required to determine whether plasma or whole blood would provide more robust data in relation to drug effect. However, because the majority of estimates were similar in both matrices, either matrix is likely to be suitable for assessing drug distribution and effect.

As expected, the limited sampling strategy with the most sampling time points (total of six samples) resulted in the lowest measures of bias for amifostine clearance. The LSM with two samples (5 and 30 min) drawn from two dosing occasions resulted in a similarly low bias estimate for amifostine clearance and a lower bias estimate for CLWR. In addition, the parameter estimates from the LSM with two samples from two occasions were not significantly different from the LSM with six samples. With 33% fewer samples required, the LSM with two samples from two occasions would be preferable in future pharmacokinetic investigations of amifostine. Although sampling from one occasion would likely provide accurate estimation of systemic amifostine clearance and volume, the estimation of CLWR using one occasion sampling models resulted in a large bias compared with the full sampling model.

In summary, we have developed a population pharmacokinetic model of amifostine and WR1065 in pediatric patients with medulloblastoma. We analyzed for the effects of covariates on amifostine pharmacokinetics using a nonlinear mixed effects approach. In the present analysis, we identified BSA as a covariate that can be used prospectively in a model to predict amifostine clearance. This analysis identified a large component of interpatient variability in clearance of both amifostine and WR1065, which may have significant implications for this clinically important therapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Lisa Walters, Terri Kuehner, Sheri Ring, Margaret Edwards, and Paula Condy for their commitment to improving patient care and their assistance in obtaining patient samples and Mark N. Kirstein and...
Susannah E. Motl-Moroney for their assistance in conducting this study.

Grant Support

NIH Cancer Center Support (CORE) grant P30 CA21765, Pediatric Brain Tumor Foundation, Musicians Against Childhood Cancer, the Noyes Brain Tumor Foundation, Ryan McGhee Foundation, and the American Lebanese Syrian Associated Charities.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/5/09; revised 11/9/09; accepted 12/2/09; published OnlineFirst 1/26/10.

References

Clinical Cancer Research

Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma

Trevor McKibbin, John C. Panetta, Maryam Fouladi, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-09-1997</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2010/01/26/1078-0432.CCR-09-1997.DC1">http://clincancerres.aacrjournals.org/content/suppl/2010/01/26/1078-0432.CCR-09-1997.DC1</a></td>
</tr>
</tbody>
</table>

| Cited articles | This article cites 32 articles, 7 of which you can access for free at: http://clincancerres.aacrjournals.org/content/16/3/1049.full#ref-list-1 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |